Search

Your search keyword '"Zübeyde Ekin"' showing total 5 results
Start Over Author "Zübeyde Ekin"
5 results on '"Zübeyde Ekin"'

1. Impression Cytologic Evaluation of the Conjunctiva in Patients Treated with Topical 1% Voriconazole

Author

Cumali Değirmenci, Melis Palamar, Zübeyde Ekin, Özlem Barut Selver, Ali Veral, and Ayşe Yağcı

Subjects
fungal keratitis, voriconazole, impression cytology, metaplasia, Medicine, Ophthalmology, RE1-994
Abstract

Objectives:The aim of the present study was to evaluate any conjunctival metaplastic changes by impression cytology in patients who underwent topical 1% voriconazole treatment for severe fungal keratitis.Materials and Methods:The study was conducted at Ege University Faculty of Medicine, Departments of Ophthalmology and Medical Pathology. Patients who were treated with 1% topical voriconazole for fungal keratitis for at least 3 months were included. The used topical voriconazole treatment was initiated as one drop every hour and was tapered according to clinical improvement in all patients. Treatment was continued 4 times a day for at least 3 months. Impression cytology samples were collected at least 3 months after cessation of topical voriconazole from the affected eyes and from the fellow eyes as a control group. Collected specimens were transferred to the pathology department for evaluation and grading (Nelson’s grading system).Results:The mean age of the patients was 57.68±17.32 years (range, 22-87 years). The impression cytology grade of the inferior bulbar conjunctiva was 1.73±0.77 (range, 0-3) in the study group and 1.19±0.98 (range, 0-3) in the control group (p=0.03). The impression cytology grade of the temporal bulbar conjunctiva was 1.69±0.73 (range, 0-3) in the study group and 1.15±0.88 (range, 0-3) in the control group (p=0.02). The impression cytology grades of the nasal and superior bulbar conjunctiva did not differ statistically (p values 0.13 and 0.17, respectively).Conclusion:Topical voriconazole is an effective broad-spectrum antifungal drug, but it induces conjunctival squamous metaplasia. Clinicians should be aware of this possible side effect of topical voriconazole and should carefully evaluate the conjunctiva of treated patients at each visit to detect possible metaplastic changes.

Published
2024
Full Text
View/download PDF

3. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma

Author

Pınar Savaş, Deniz Nart, Ali Veral, and Zübeyde Ekin

Subjects
Adult, Male, medicine.medical_specialty, Lung Neoplasms, Specimens, Cytodiagnosis, Smears, Expression, Gastroenterology, B7-H1 Antigen, Cytology, Internal medicine, PD-L1, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins, ROS1, Carcinoma, Medicine, Humans, Anaplastic Lymphoma Kinase, Epidermal growth factor receptor, Lung cancer, Selection, Cancer, Aged, Retrospective Studies, Aged, 80 and over, Lung, biology, business.industry, In-Situ Hybridization, Receptor Protein-Tyrosine Kinases, Reproducibility of Results, Histology, Middle Aged, Protein-Tyrosine Kinases, medicine.disease, ErbB Receptors, medicine.anatomical_structure, Cross-Sectional Studies, biology.protein, Female, Heterogeneity, business, Reactive Oxygen Species
Abstract

Background The expression levels of Programmed death ligand-1 (PD-L1), epidermal growth factor receptor (EGFR), anaplastic lymphoma tyrosine kinase gene (ALK), and proto-oncogene tyrosineprotein kinase 1 ROS (ROS1) are important for targeted treatment selection in advanced lung cancer. Most patients with lung cancer are diagnosed at an advanced stage and have no chance of surgery. For this reason, the accuracy and reliability of cytology samples for detecting those markers is important in patients whose histological sampling cannot be performed. Aims To test the compatibility of histological and cytological sample analysis results of EGFR, ALK, ROS1 and PDL-1 in patients with NSCLC and to determine the adequacy of cytological analysis for PD-L1 expression. Study design Retrospective cross-sectional study. Methods The results of 231 patients whose PD-L1 was studied in 2018 were analyzed retrospectively. We excluded 11 inappropriate samples. A total of 220 samples were distributed as follows; 66 (30.0%) cytology specimens, 64 (29.1%) small histology biopsies, and 90 (40.9%) surgical biopsies. EGFR, ALK, ROS1 and PD-L1 analysis were performed in 139, 134, 116, and 220 patients, respectively. Samples containing >400 cells were considered suitable for molecular cytological study. Results A total of 154 (70.0%) histological (surgical biopsy) and 66 (30.0%) cytology samples were analyzed. There was no statistically significant difference between histological and cytological samples in terms of cellular adequacy for all molecular markers [EGFR: 93.7% and 90.9% (P = .556), ALK: 97.8% and 95.3% (P = .436) , ROS1: 89.9% vs. 91.9% (P = .729), PD-L1: 95.5% vs. 92.4% (P = .364)]. There was no statistically significant difference in the expression positivity rates of all biomarkers between histological and cytological samples [EGFR: 9.0% vs. 2.5% (P = .018), ALK: 7.9% vs. 9.8% (P = .719), ROS1 : 1.4% vs. 2.9% (P = .591), PD-L1: 54.4% vs. 41.0% (P = .078)]. Conclusion The cellular adequacy of cytology specimens for molecular testing in patients with NSCLC is satisfactory. This study shows that EGFR, ALK, ROS-1 and PDL-1 expression rates in cytological samples are not statistically different from histological samples.

Published
2021

4. Comparison of Eosinophilic and Non-eosinophilic Cases with Chronic Obstructive Pulmonary Disease (COPD) in Terms of Clinical Arrival, Exacerbations, Quality of Life and Response to Treatment: A Prospective Study

Author

Abdullah Sayiner, Deniz Nart, Alev Gürgün, Zübeyde Ekin, Yagmur Kaptan, Aslı Sunel, Funda Elmas Uysal, and Ege Üniversitesi

Subjects
medicine.medical_specialty, COPD, Quality of life, business.industry, Internal medicine, Eosinophilic, COPD - management, medicine, Pulmonary disease, business, Prospective cohort study, medicine.disease, Response to treatment
Abstract

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN, WOS: 000507372403105, [No abstract available], European Respiratory Soc

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results